Find a Doctor

Carel B. Hoyng
CH
Areas of Expertise

Carel B. Hoyng

Radboud University Medical Center

Bio

Carel Hoyng is in Nijmegen, Netherlands. They have been an author on 263 peer reviewed articles and participated in 2 clinical trials in the past 15 years.

Areas of Expertise

Contact

Nijmegen, GE, NL

Latest Research

Latest Advance
Study
  • Condition: Diabetic Macular Edema
  • Journal: Ophthalmology. Retina
  • Treatment Used: Bevacizumab or Ranibizumab
  • Number of Patients: 170
  • Published —
This study compared the clinical outcome of using bevacizumab or ranibizumab to treat patients with diabetic macular edema.
Latest Advance
Study
  • Condition: Chronic Central Serous Chorioretinopathy (cCSC)
  • Journal: American journal of ophthalmology
  • Treatment Used: Crossover to Photodynamic Therapy (PDT) or Micropulse Laser After Failed Primary Treatment
  • Number of Patients: 42
  • Published —
This study assessed whether patients with chronic central serous chorioretinopathy (condition in which fluid accumulates under the retina; cCSC) patients without a complete resolution of subretinal fluid (accumulation of a clear or lipid-rich fluid) in the subretinal space; SRF) after either half-dose photodynamic therapy (two-stage treatment that combines light energy with a drug; PDT) or high-density subthreshold micropulse laser (incorporate a higher density of laser spots and much lower power; HSML) treatment would benefit from crossover treatment.
Latest Advance
Study
  • Condition: Retinal Vein Occlusion (RVO)
  • Journal: Ophthalmology. Retina
  • Treatment Used: Bevacizumab vs. Ranibizumab
  • Number of Patients: 0
  • Published —
This study compared the effectiveness of intravitreal injections of bevacizumab to ranibizumab in the treatment of macular edema (swelling; ME) resulting from retinal vein occlusion (RVO).
Latest Advance
Study
  • Condition: Diabetic Macular Edema (DME)
  • Journal: Ophthalmology. Retina
  • Treatment Used: Intravitreal Afilbercept
  • Number of Patients: 553
  • Published —
This study evaluated the vision-related quality of life in patients with diabetic macular edema (accumulation of fluid in the macula part of the retina due to leaking blood vessels; DME) treated with intravitreal (medication delivered directly into the space in the back of the eye called the vitreous cavity) afilbercept.
Latest Advance
Study
  • Condition: Focal and Diffuse Chronic Central Serous Chorioretinopathy
  • Journal: American journal of ophthalmology
  • Treatment Used: Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser
  • Number of Patients: 156
  • Published —
This study compared the clinical outcome of using a half-dose photodynamic therapy or a subthreshold micropulse laser to treat patients with focal and diffuse chronic central serous chorioretinopathy.
Latest Advance
Study
  • Condition: Birdshot chorioretinopathy
  • Journal: Retina (Philadelphia, Pa.)
  • Treatment Used: Adalimumab
  • Number of Patients: 19
  • Published —
The study researched the safety and effectiveness of Adalimumab for birdshot chorioretinopathy.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2/Phase 3
  • Intervention Type: Other, Drug
  • Participants: 30
  • Start Date: April 4, 2019
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Clinical Trial
  • Status: Recruiting
  • Participants: 40
  • Start Date: December 17, 2017
Natural History Study of CEP290-Related Retinal Degeneration

All Publications
View All

Publication
Conference
  • Sponsor: American Society of Human Genetics (ASHG)
  • Event Name: American Society of Human Genetics Annual Meeting 2020
  • Published —
Structural variants create new topological associated domains and ectopic retinal enhancer-gene contact in dominant retinitispigmentosa.
Publication
Study
  • Journal: American journal of ophthalmology
  • Published —
Reply to Comment on: Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy.

Contact

Nijmegen, GE, NL

Insurance

Contact them to find out if they accept your insurance plan.